LSV Asset Management Has $508.91 Million Stake in Gilead Sciences, Inc. $GILD

LSV Asset Management decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,146,280 shares of the biopharmaceutical company’s stock after selling 153,313 shares during the period. Gilead Sciences accounts for about 1.1% of LSV Asset Management’s investment portfolio, making the stock its 11th biggest holding. LSV Asset Management’s holdings in Gilead Sciences were worth $508,914,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Paulson Wealth Management Inc. grew its position in shares of Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares during the period. Alpha Cubed Investments LLC grew its position in shares of Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares during the period. Personal CFO Solutions LLC grew its position in shares of Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares during the period. Moss Adams Wealth Advisors LLC grew its position in shares of Gilead Sciences by 1.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after buying an additional 76 shares during the period. Finally, Valued Wealth Advisors LLC grew its position in shares of Gilead Sciences by 12.5% during the 4th quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 79 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $134.36 on Friday. The company has a fifty day simple moving average of $136.27 and a 200 day simple moving average of $133.65. Gilead Sciences, Inc. has a 12-month low of $104.46 and a 12-month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The company has a market cap of $166.82 billion, a P/E ratio of 18.31 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter last year, the firm posted $1.81 EPS. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is currently 44.69%.

Analysts Set New Price Targets

Several brokerages have recently commented on GILD. Oppenheimer raised their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Mizuho lifted their price target on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Argus lifted their price target on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Finally, Citigroup lifted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $156.93.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to Hepcludex (bulevirtide-gmod) for chronic hepatitis delta virus (HDV), making it the first and only approved treatment in the U.S. for this rare and serious liver disease. That opens a new commercial opportunity in a high-unmet-need market. Article Title
• Positive Sentiment: Gilead also received a CHMP positive opinion in Europe for Trodelvy in first-line metastatic triple-negative breast cancer, supporting broader international adoption of one of its key oncology products. Article Title
• Positive Sentiment: Gilead completed its Tubulis acquisition, adding next-generation antibody-drug conjugate assets and strengthening its oncology pipeline. Article Title
• Positive Sentiment: Analysts at Zacks Research raised near-term EPS estimates for some periods and maintained strong longer-term profit expectations, which can support investor confidence in Gilead’s earnings outlook. Article Title
• Neutral Sentiment: Gilead announced a renewed collaboration with the World Health Organization to help eliminate visceral leishmaniasis, a public-health initiative that is strategically positive but likely not an immediate stock driver. Article Title
• Negative Sentiment: Some analyst updates trimmed certain 2026–2028 earnings estimates, which may temper enthusiasm around the stock’s longer-term growth rate, even as recent product news remains favorable. Article Title

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at $22,907,973.57. The trade was a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the transaction, the chief executive officer directly owned 632,567 shares in the company, valued at $81,702,353.72. This represents a 1.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,000 shares of company stock valued at $8,523,570 in the last three months. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.